Interventional, Open-label, Positron Emission Tomography (PET) Study Investigating the Brain Receptor Occupancy of Idalopirdine in Patients With Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2018
Price : $35 *
At a glance
- Drugs Idalopirdine (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Lundbeck A/S
- 03 Apr 2018 Status changed to discontinued due to strategic reasons.
- 02 Mar 2018 Status changed from recruiting to completed.
- 21 Nov 2017 Planned End Date changed from 1 Nov 2017 to 1 Jan 2018.